Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Innate Pharma (IPHYF) over the last 5 years, with Q2 2025 value amounting to 1.5%.

  • Innate Pharma's Return on Capital Employed fell 7900.0% to 1.5% in Q2 2025 from the same period last year, while for Jun 2025 it was 1.5%, marking a year-over-year decrease of 7900.0%. This contributed to the annual value of 0.47% for FY2024, which is 3800.0% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Return on Capital Employed is 1.5%, which was down 7900.0% from 0.85% recorded in Q4 2024.
  • Innate Pharma's Return on Capital Employed's 5-year high stood at 0.35% during Q4 2021, with a 5-year trough of 1.5% in Q2 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.71% (2024), whereas its average is 0.76%.
  • In the last 5 years, Innate Pharma's Return on Capital Employed plummeted by -1000bps in 2024 and then crashed by -7900bps in 2025.
  • Innate Pharma's Return on Capital Employed (Quarter) stood at 0.35% in 2021, then tumbled by -53bps to 0.53% in 2022, then tumbled by -42bps to 0.75% in 2023, then dropped by -14bps to 0.85% in 2024, then plummeted by -77bps to 1.5% in 2025.
  • Its Return on Capital Employed stands at 1.5% for Q2 2025, versus 0.85% for Q4 2024 and 0.71% for Q2 2024.